Phaseline

Targets › ITGB6

ITGB6 (Integrin beta-6): drug programs, companies and trials

4 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. (UniProt, P18564)

Open in Phaseline: the race on ITGB6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pfizersigvotatug vedotin
Integrin beta-6 binding agent
ITGB6Phase 3Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small Cell LungJun 2027
PfizerSigvotatug Vedotin
Integrin beta-6 binding agent
ITGB6Phase 3Non-Small Cell Lung Cancer; Advanced/Metastatic Non-Small Cell Lung CancerSep 2028
University of California, Davis[18F]-αvβ6-BP
Fluorine-18-labeled αvβ6 integrin-binding peptide for PET imaging
ITGAV, ITGB6Phase 1Lung CancerDec 2026
Sutro BiopharmaSTRO-006
ITGB6-targeting antibody-drug conjugate
ITGB6Phase 1Head & Neck Squamous Cell CarcinomaFeb 2028

Conditions

Carcinoma, Non-Small-Cell Lung (1) Carcinoma, Non-Small Cell Lung (1) Lung Cancer (1) Non-Small Cell Lung Cancer (1) Advanced/Metastatic Non-Small Cell Lung Cancer (1) Head & Neck Squamous Cell Carcinoma (1)

Modalities

mixed (2), small molecule (1), antibody (1)

Companies

Pfizer (2) University of California, Davis (1) Sutro Biopharma (1)

Related targets

ITGAV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.